Bacterial-Derived Therapeutics based on CircRNAs (BacTheRNA)

Informazioni relative al progetto

BacTheRNA

ID dell’accordo di sovvenzione: 101065819

DOI

10.3030/101065819

Progetto concluso il 7 Novembre 2023

Data della firma CE 21 Giugno 2022

Data di avvio 16 Luglio 2022

Data di completamento 15 Maggio 2024

Finanziato da

• Marie Skłodowska-Curie Actions (MSCA)

Costo totale

Nessun dato

Contributo UE

€ 172 750,08

Coordinato da

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Ireland

Periodic Reporting for period 1 - BacTheRNA (Bacterial-Derived Therapeutics based on CircRNAs (BacTheRNA))

Periodo di rendicontazione: 2022-07-16 al 2024-05-15

Sintesi del contesto e degli obiettivi generali del progetto

Probiotic bacteria are beneficial to the host in several ways. The final goal of BacTheRNA is the development of novel RNA-based therapeutics using probiotic bacteria. These can be used as a biological production factory for RNA therapeutics, at a cheaper cost than chemical synthetic routes. Due to their being harmless and food-grade, they represent a safe and low-cost alternative to current methods.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

This project was terminated early so it did not reach its full objectives and potential. However, in the months of implementation, preliminary results were achieved that could set the basis for further research. A suitable probiotic strain was selected, and DNA plasmids were designed (but not tested or validated) to perform subsequent experiments. Particular RNA targets naturally produced by these bacteria were also studied, yielding preliminary results.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Due to the short duration of the project, the impact could not be fully achieved. The results achieved are preliminary.